Track Voyager Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Voyager Therapeutics, Inc. VYGR · Stock Open Voyager Therapeutics, Inc. in new tab

1.73 USD
P/E
6.45
EPS
-1.74
P/B
0.84
ROE
-58.90
Beta
1.17
Target Price
14.22 USD
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
P/E6.45
EPS-1.74
Book Value2.17
Price to Book0.84
Debt/Equity22.58
% Insiders14.805%
Growth
Revenue Growth-0.70%
Estimates
Forward P/E-1.48
Forward EPS-1.24
Target Mean Price14.22

DCF valuation

Model fair value for Voyager Therapeutics, Inc. (VYGR)
Result
Sign in to run the valuation for VYGR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Strong buy · mean target 14.22 USD (low 8.00, high 25.00) · as of 10 Nov 2026
Low 8.00
Mean 14.22
High 25.00
Price 1.73
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Voyager Therapeutics, Inc. Logo Voyager Therapeutics, Inc. Analysis (VYGR)

United States Health Care Official Website Stock

Is Voyager Therapeutics, Inc. a good investment? Voyager Therapeutics, Inc. (VYGR) is currently trading at 1.73 USD. Market analysts have a consensus price target of 14.22 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 6.45. This relatively low multiple may signal that Voyager Therapeutics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Voyager Therapeutics, Inc. is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -1.24.

Investor FAQ

Does Voyager Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Voyager Therapeutics, Inc.?

Voyager Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -1.74.

Company Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Exchange Ticker
NMS (United States) VYGR
FRA (Germany) VT6.F
MEX (Mexico) VYGR.MX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion